Rozlytrek, approved Aug. 15, targets solid tumors that show rare genetic defects called NTRK gene fusions and ROS1-positive non-small cell lung cancer.
Eli Lilly and Bayer’s drug Vitrakvi is priced at $32,800 per month. It also treats tumors with NTRK gene fusions.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
